Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2001
10/30/2001US6309648 Induces formation of protective antibodies against an infection by a bacteria selected from the group consisting of b. pertussis, b. parapertussis, and b. bronchiseptica when administered to a human or animal host.
10/30/2001US6309647 The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus.
10/30/2001US6309646 Derivatizing a polysaccharide with thiols, amines, or hydrazides; reacting the derivatized polysaccharide with a vinylsulfone group; reacting the product with a protein, a peptide, or a hapten
10/30/2001US6309645 A method of suppressing an immune response in a mammal.
10/30/2001US6309644 Parasitic nematode transglutaminase proteins and uses thereof
10/30/2001US6309642 Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
10/30/2001US6309641 Which can be used immunologically as a vaccine for leptospirosis caused by this organism.
10/30/2001US6309640 Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
10/30/2001CA2090700C Modified antibodies with controlled clearance time
10/30/2001CA2047843C Method and product for the treatment of gastric disease
10/27/2001CA2345444A1 Novel therapeutic processes and useful compositions therefor
10/25/2001WO2001079555A2 Roles of jak/stat family members in tolerance induction
10/25/2001WO2001079525A2 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
10/25/2001WO2001079511A2 Hemolysin fusion proteins, their production and use
10/25/2001WO2001079510A1 Materials and methods relating to immune responses to fusion proteins
10/25/2001WO2001079480A1 Albumin fusion proteins
10/25/2001WO2001079444A2 Albumin fusion proteins
10/25/2001WO2001079443A2 Albumin fusion proteins
10/25/2001WO2001079442A2 Albumin fusion proteins
10/25/2001WO2001079300A1 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
10/25/2001WO2001079299A1 Enhancement of antibody-mediated immune responses
10/25/2001WO2001079298A1 Novel recombinant antibodies, amino acid sequences of cdrs thereof and genes encoding the same
10/25/2001WO2001079296A1 Humar emr2, a g-protein coupled receptor from the egf-tm7 family
10/25/2001WO2001079291A2 Secreted proteins
10/25/2001WO2001079288A2 Cytokine uses; compositions; methods
10/25/2001WO2001079286A2 Compositions and methods for the therapy and diagnosis of breast cancer
10/25/2001WO2001079282A2 Molecules associated with human reproduction
10/25/2001WO2001079281A1 Sheep lice, bovicola ovis, allergen treatment
10/25/2001WO2001079277A2 Immunogenic pili presenting foreign peptides, their production and use
10/25/2001WO2001079276A2 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
10/25/2001WO2001079274A2 Tuberculosis antigens and methods of use thereof
10/25/2001WO2001079273A2 Viruses comprising mutated ion channel protein
10/25/2001WO2001079271A1 Albumin fusion proteins
10/25/2001WO2001079259A1 Javelinization of protein antigens to heat shock proteins
10/25/2001WO2001079258A1 Albumin fusion proteins
10/25/2001WO2001079253A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001WO2001078787A2 Lipopolysaccharide-conjugate vaccine for sepsis treatment
10/25/2001WO2001078779A2 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001WO2001078777A2 Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
10/25/2001WO2001078776A1 Herpes virus complementing cell line
10/25/2001WO2001078775A2 A method for making an hiv vaccine
10/25/2001WO2001078774A2 Recombinant intracellular pathogen vaccines and methods for use
10/25/2001WO2001078773A2 Dissociated pili, their production and use
10/25/2001WO2001078772A1 Heat shock protein-based antiviral vaccines
10/25/2001WO2001078770A1 Inhibition of transmission of tick-borne infections
10/25/2001WO2001078769A2 Regulation of systemic immune responses utilizing soluble cd40
10/25/2001WO2001078768A2 Targeted vaccine delivery systems
10/25/2001WO2001078767A2 Pharmaceutical preparations comprising modified peptides
10/25/2001WO2001078766A1 Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
10/25/2001WO2001078748A2 Immunomodulatory methods using carbohydrate antigens
10/25/2001WO2001078707A1 Treating graft rejection with ccr5 inhibitors
10/25/2001WO2001078655A2 Methods and compositions for heat shock protein mediated immunotherapy of melanoma
10/25/2001WO2001078650A2 Vaccines for protection against borrelia burgdorferi
10/25/2001WO2001049317A9 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
10/25/2001WO2001039786A3 New uses of suppressive macrophage activation factors
10/25/2001WO2001026679A3 T-cells and molecules involved in immune regulation
10/25/2001WO2001023597A3 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
10/25/2001WO2001023421A3 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
10/25/2001WO2001022993A3 MUCOSAL DTPa VACCINES
10/25/2001WO2001012790A3 Isomerase proteins
10/25/2001WO2001000245A3 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
10/25/2001WO2000047104A3 Antagonists of hmg1 for treating inflammatory conditions
10/25/2001WO1999057267A3 Human epididymal glytathione peroxidase
10/25/2001US20010034436 Polynucleotide and polypeptides, screening for antibiotic activity, Staphylococcus
10/25/2001US20010034330 Administering a mixture containing dinucleotide
10/25/2001US20010034327 Suppression of inhibitors
10/25/2001US20010034052 A breast tumor polypeptide(s), immunogenic portions thereof, polynucleotides that encode such peptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides; vaccines
10/25/2001US20010034042 Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
10/25/2001US20010034021 Antibodies that specifically react with seroreactive regions on HPV 16 proteins E1 and E2
10/25/2001US20010034018 Contacting a sample with an antibody which binds to SVI (Sentinel virus 1) or a protein and the antibody does not bind TTV strains SANBAN and TUS01 or protiens and detecting the complexes of antibody and SVI virus or protein
10/25/2001US20010033845 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
10/25/2001US20010033844 Human Herpesvirus 6A and 6B transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis
10/25/2001US20010033841 Atherosclerosis therapy
10/25/2001US20010033840 Methods for inducing T cell tolerance to a tissue or organ graft
10/25/2001US20010033839 Vaccine kits
10/25/2001US20010033836 Transgenic autologous T-cell therapy in humans, and related compositions and kits
10/25/2001US20010033833 Side effect reduction
10/25/2001DE10019967A1 New recombinant antibody specific for native gp96, useful for isolating gp96 as complex with endogenous peptides, used for autologous immunotherapy of e.g. tumor
10/25/2001DE10018681A1 Composition for autologous tumor treatment, comprises extracellular material produced by culturing immune competent cells with tumor cells that lack membrane surface substances
10/25/2001DE10016846A1 New cell constructs from activated T-cells of patients useful as a medicament
10/25/2001CA2747325A1 Albumin fusion proteins
10/25/2001CA2406955A1 Sheep lice, bovicola ovis, allergen treatment
10/25/2001CA2406472A1 Javelinization of protein antigens to heat shock proteins
10/25/2001CA2406378A1 Targeted vaccine delivery systems
10/25/2001CA2406245A1 Il-174 uses, compositions and methods
10/25/2001CA2406220A1 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001CA2406213A1 Compositions and methods for the therapy and diagnosis of breast cancer
10/25/2001CA2406180A1 Viruses comprising mutant ion channel protein
10/25/2001CA2406126A1 Humar emr2, a g-protein coupled receptor from the egf-tm7 family
10/25/2001CA2405781A1 Secreted proteins
10/25/2001CA2405709A1 Albumin fusion proteins
10/25/2001CA2405701A1 Albumin fusion proteins
10/25/2001CA2405563A1 Albumin fusion proteins
10/25/2001CA2405557A1 Albumin fusion proteins
10/25/2001CA2405550A1 Albumin fusion proteins
10/25/2001CA2405525A1 Albumin fusion proteins
10/25/2001CA2405451A1 Molecules associated with human reproduction
10/25/2001CA2405247A1 Tuberculosis antigens and methods of use thereof
10/25/2001CA2403547A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
10/25/2001CA2403508A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
1 ... 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 ... 1823